Allergan's eyelash drug may expand options for some patients
The recent announcement by Allergan that its new eyelash-enhancing drug is moving toward approval has plastic surgeons looking forward to a cosmetic enhancement that some say will be quite popular with patients and could provide a nice boost to plastic surgery practices.
Allergan, based in Irvine, CA, recently announced that it intends to file a new drug application by the end of the third quarter of this year with the FDA for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.
Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in -significant eyelash growth, says Scott Whitcup, MD, executive vice president of research and development at Allergan.
- CVS Ramps Up Retail Clinics with Provider Affiliations
- Drug Pricing 'Tantamount to Greed,' Lawmaker Says
- Contradictory Obamacare Rulings Issued by Appellate Courts
- Study Puts Spotlight on Preventing Fall-Related Injuries
- Wanted: Nurse PhDs
- As HIPAA Breaches Accelerate, Tools Lag
- The Infection-Busting Treatment Payers Don’t Want to Talk About
- 4 Tectonic Shifts Shaking Up Healthcare
- Surgical Checklists Unused in 10% of Hospitals, CMS Data Shows
- Roundtable: Life After a Healthcare Organization Acquisition